药物信息为Cafergot (Novartis Pharmaceuticals Corporation): WARNING

Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of CAFERGOT^® (ergotamine tartrate and caffeine) with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of CAFERGOT, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See CONTRAINDICATIONS and WARNINGS)